Table 3.

Remission of obesity-associated comorbidities between sleeve gastrectomy groups (COV-group vs. CONTROL-group) at 1-year follow-up

	COV-group, n=45	CONTROL-group, n=57	p
T2DM remission	12 out of 21 (57.1%)	20 out of 30 (66.7%)	0.48
HTN remission	15 out of 25 (60.0%)	21 out of 29 (72.4%)	0.33
Dyslipidemia remission	20 out of 28 (71.4%)	29 out of 34 (85.3%)	0.18
OSA remission	5 out of 12 (41.7%)	9 out of 17 (52.9%)	0.55

T2DM type 2 diabetes mellitus, HTN hypertension, OSA obstructive sleep apnea syndrome